A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

Clinical trial NCT04361279 · COMPLETED

Trial details

NCT number: NCT04361279
Sponsor: Shanghai Institute Of Biological Products
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma

Start date: 2019-07-25
Primary completion: 2022-05-20
Enrollment: 421

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.